Seladelpar in patients with primary biliary cholangitis: Need for a closer look!
- PMID: 35594993
- DOI: 10.1016/j.jhep.2022.04.039
Seladelpar in patients with primary biliary cholangitis: Need for a closer look!
Keywords: Fibrosis; PBC; PPAR delta; Seladelpar; UDCA.
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!".J Hepatol. 2022 Nov;77(5):1452-1453. doi: 10.1016/j.jhep.2022.07.024. Epub 2022 Aug 14. J Hepatol. 2022. PMID: 35977610 No abstract available.
Comment on
-
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.J Hepatol. 2022 Aug;77(2):353-364. doi: 10.1016/j.jhep.2022.02.033. Epub 2022 Mar 30. J Hepatol. 2022. PMID: 35367282 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
